Association between non-adherence to fish oil or placebo as a risk factor of transition to psychosis in ultra-high-risk individuals in the NEURAPRO study

M Schlögelhofer; A Lin; C Markulev; MR Schäfer; PD McGorry; B Nelson; R Street; N Mossaheb; S Smesny; IB Hickie; G Berger; EYH Chen; L de Haan; DH Nieman; M Nordentoft; A Riecher-Rössler; S Verma; A Thompson; AR Yung; GP Amminger

Journal article

Association between non-adherence to fish oil or placebo as a risk factor of transition to psychosis in ultra-high-risk individuals in the NEURAPRO study

M Schlögelhofer, A Lin, C Markulev, MR Schäfer, PD McGorry, B Nelson, R Street, N Mossaheb, S Smesny, IB Hickie, G Berger, EYH Chen, L de Haan, DH Nieman, M Nordentoft, A Riecher-Rössler, S Verma, A Thompson, AR Yung, GP Amminger

Australian and New Zealand Journal of Psychiatry | Published : 2025

DOI: 10.1177/00048674251361758

Abstract

Objective: Non-adherence is an important factor in clinical trials, which has not been investigated in people at ultra-high risk (UHR) of developing a first episode of psychosis. Methods: Exploratory analysis of data from NEURAPRO, a multicenter, placebo-controlled trial of long-chain omega-3 polyunsaturated fatty acids (omega-3 PUFAs) in 304 individuals at UHR. We examined correlates of non-adherence with study medication (omega-3 PUFAs or placebo), including patient, illness and treatment factors, plus transition to psychosis. Non-adherence was defined as <75% study medication intake over 6 months and, post hoc, by the number of returned pills. Results: Of 285 randomized participants with ..

View full abstract

University of Melbourne Researchers

Connie Markulev Author

Patrick McGorry Author

Barnaby Nelson Author

Rebekah Street Author

Related Projects (4)

EMERGING MENTAL DISORDERS IN YOUNG PEOPLE: USING CLINICAL STAGING FOR PREDICTION, PREVENTION AND EARLY INTERVENTION

Mental disorders are a major cause of disability in Australia, especially for young people. We have developed a clinical staging model cover..

LIPID BIOLOGY FOR PREDICTION AND PREVENTION OF PSYCHOTIC DISORDERS AND PERSISTENT DEPRESSION IN YOUNG PEOPLE

My vision for the next 5 years is to establish ω-3PUFAs as a first-line treatment for indicated prevention of psychosis and persistent depre..

MAPPING AND TREATING EARLY CLINICAL STAGES OF MENTAL DISORDERS DURING TRANSITION TO ADULTHOOD

The research proposed in this Fellowship is aimed at young people with emerging mental ill-health. The specific goals and targets are to for..

CLINICAL PREDICTORS OF OUTCOME IN THE ULTRA HIGH RISK FOR PSYCHOSIS ("PRODROMAL") POPULATION

This area of research is concerned with improving our ability to identify young help-seeking patients who are most at risk of developing psy..

Grants

Citation metrics

1Scopus

1Dimensions

Keywords

Mental Health

Clinical Research

Ultra-High Risk

Serious Mental Illness

Dietary Supplements

Non-Adherence

Nutrition

3214 Pharmacology and Pharmaceutical Sciences

Behavioral and Social Science

Omega-3 Polyunsaturated Fatty Acids (omega-3 Pufas)

Psychosis

Complementary and Integrative Health

6.1 Pharmaceuticals

Clinical Trials and Supportive Activities

32 Biomedical and Clinical Sciences